We are live on ! Find out more
GS

Gilead Sciences Portfolio holdings

AUM $2.12B
1-Year Est. Return 143.53%
This Fund
S&P 500
This Quarter Est. Return
+14.14%
1 Year Est. Return
+143.53%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.28B
AUM Growth
+$98.9M
Cap. Flow
-$3.06M
Cap. Flow %
-0.24%
Top 10 Hldgs %
99.79%
Holding
14
New
–
Increased
–
Reduced
3
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
KLRS
Kalaris Therapeutics
KLRS
+$1.83M
2
IMA
ImageneBio Inc
IMA
+$992K
3
BRNS
Barinthus Biotherapeutics
BRNS
+$236K

Sector Composition

Rank Sector Weight
1 Healthcare 99.88%
2 Financials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LKFT
1
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.78B
$468M 36.53%
16,707,477
– –
ACLX
2
DELISTED
Arcellx
ACLX
$443M 34.57%
6,720,803
– –
RCUS icon
3
Arcus Biosciences
RCUS
$3.55B
$256M 19.98%
31,424,760
– –
ASMB icon
4
Assembly Biosciences
ASMB
$498M
$40M 3.13%
2,209,471
– –
TNGX icon
5
Tango Therapeutics
TNGX
$4.43B
$24.9M 1.94%
4,854,443
– –
MRUS
6
DELISTED
Merus
MRUS
$23.8M 1.86%
452,527
– –
KYTX icon
7
Kyverna Therapeutics
KYTX
$444M
$12.7M 0.99%
4,126,119
– –
XLO icon
8
Xilio Therapeutics
XLO
$59.9M
$6.19M 0.48%
650,389
– –
HOOK
9
DELISTED
HOOKIPA Pharma
HOOK
$2.35M 0.18%
1,875,945
– –
CYPH
10
Cypherpunk Technologies Inc
CYPH
$62.9M
$1.58M 0.12%
5,319,148
– –
ALLO icon
11
Allogene Therapeutics
ALLO
$649M
$1.31M 0.1%
1,156,689
– –
KLRS
12
Kalaris Therapeutics
KLRS
$83.5M
$848K 0.07%
317,789
-405,484
-56% -$1.83M
IMA
13
ImageneBio Inc
IMA
$63M
$467K 0.04%
29,045
-67,550
-70% -$992K
BRNS
14
Barinthus Biotherapeutics
BRNS
$22.8M
$92.5K 0.01%
99,478
-270,377
-73% -$236K

Similar funds

BCM
Basswood Capital Management New York $2.12B AUM 19.53% 1-Year Est. Return
IVAV
Index Venture Associates VI St. Helier, Channel Islands, Jersey $2.11B AUM 13.76% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
HJGA
Hardman Johnston Global Advisors Stamford, Connecticut $2.1B AUM 41.89% 1-Year Est. Return
CF
Centaurus Financial Anaheim, California $2.1B AUM 21.28% 1-Year Est. Return
BWC
Blue Whale Capital London, United Kingdom $2.1B AUM 97.03% 1-Year Est. Return
SFS
Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return
AAP
Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return

Gilead Sciences's Q2 2025 Portfolio in Review

As of Q2 2025, Gilead Sciences held 14 positions worth $1.28B, up 8.4% from $1.18B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q2 2025: portfolio turnover was 0%. Gilead Sciences opened no new positions and made no exits, leaving the 14-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • Gilead Sciences's biggest Q2 2025 reduction was Kalaris Therapeutics, cutting an estimated $1.83M.
  • Gilead Sciences's ten largest holdings make up 100% of its $1.28B portfolio in Q2 2025.
  • Gilead Sciences opened 0 new positions and closed 0 in Q2 2025.
  • Gilead Sciences's portfolio value rose 8.4% quarter-over-quarter to $1.28B.

Based on Gilead Sciences's 13F filing for Q2 2025, filed 14 Aug 2025.